Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

100.03 -0.62 (-0.62%)
Streaming Delayed Price Updated: 1:18 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,105,073
Open 100.35
Bid (Size) 100.02 (3)
Ask (Size) 100.03 (1)
Prev. Close 100.65
Today's Range 99.68 - 100.36
52wk Range 74.09 - 105.56
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Amazon Considers Launching Ad-Supported Prime Video Tier, Google & Microsoft Face Backlash For Ad Inclusion In AI Trials, Airbus Records One-Third Jump In May Deliveries: Today's Top Stories
Wall Street Journal 
Via Benzinga
Novartis' Sandoz Foresees Rapid Growth Post Spin-Off in Generics Market Amid Upcoming Patent Expirations
Novartis AG's (NYSE: NVS) generics unit Sandoz tells investors it can add $3 billion in annual sales over the next five years from launching new products after it spins out of its  
Via Benzinga

Performance

YTD
+8.48%
+8.48%
1 Month
-4.46%
-4.46%
3 Month
+24.99%
+24.99%
6 Month
+9.23%
+9.23%
1 Year
+14.52%
+14.52%

More News

Read More
Is Novartis a Good Stock to Buy Right Now?
Via The Motley Fool
Veterinary Healthcare Product Market to See Huge Growth : Pfizer, Merck, Johnson & Johnson
Via SBWire
Looking At Novartis's Recent Unusual Options Activity
Via Benzinga
Avrobio Offloads Gene Therapy Program For Rare Genetic Disorder To Novartis
Via Benzinga
Regeneron Pharma Dives As Competition Undercuts Its Biggest Moneymaker
Via Investor's Business Daily
Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application
Via MarketBeat
Topics Death
Exposures Death Product Safety
Smokeless Tobacco Treatment Market to See Booming Growth : Novartis, Pfizer, Johnson & Johnson, Cambrex
Via SBWire
Exposures Climate
Avrobio Stock Jumps On Sale Of Gene Therapy Program To Novartis
Via Benzinga
Is This Big Pharma Stock a Buy for Dividend Investors?
Via The Motley Fool
The Global Metastatic Breast Cancer Treatment Market Expected To Reach $31 Billion By 2028
Via FinancialNewsMedia
Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis
Via Benzinga
Why Is AVROBIO (AVRO) Stock Up 83% Today?
Via InvestorPlace
Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Via MarketBeat
Topics Economy
Exposures Economy
Oral Cancer Treatment Market Projected to Show Strong Growth : Bristol-Myers Squibb, Qilu Pharmaceutical, Novartis
Via SBWire
AI for Pharma and Biotech Market Giants Spending Is Going to Boom : PFIZER, Abbott, SANOFI, Atomwise
Via SBWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance
Via Benzinga
What's Going On With Immix Biopharma Stock Today
Via Benzinga
Amgen vs. Sandoz: Legal Battle Erupts Over Bone-Strengthening Drug Patents
Via Benzinga
Johnson & Johnson Ignites CAR-T Ambitions With Licensing Pact With Cellular Biomedicine
Via Benzinga
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
Via FinancialNewsMedia
Exposures COVID-19
Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review
Via Investor's Business Daily
Rare Blood Disorder Treatment Breakthrough: Novartis' Candidate Improves Hemoglobin To Near-Normal Levels
Via Benzinga
After Q1 Review, Novartis Narrows R&D Pipeline To Prioritize High-Value Transformative Medicines
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.